Company Profile

Genomic Vision is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics






Quest Diagnostics, Madison, NJ, USA

The strategic partnership of Genomic Vision with Quest Diagnostics was signed in November 2010. Quest Diagnostics is the world’s leading provider of diagnostic information services and has unrivalled capabilities to market and perform molecular diagnostics tests. Under the terms of this multi-year agreement, Quest Diagnostics has exclusive rights to offer Molecular Combing-based testing in the USA, India and Mexico. Quest Diagnostics has also made an equity investment in Genomic Vision. Quest Diagnostics has recently presented results of the validation of the FSHD diagnostics test, based on Molecular Combing, in international scientific conferences.



La Timone Hospital, Marseille, France

Genomic Vision and the Assistance Publique ‐ Hôpitaux de Marseille along with the Université de la Méditérrannée have concluded a co-development agreement in 2006. Bringing together the expertise of Prof. Nicolas Lévy from the La Timone Hospital, a world-class clinical expert genetic diseases, and the capabilities of Genomic Vision for the development of innovative tests resulted in the successful development of a diagnostics test for facioscapulohumeral dystrophy (FSHD), which is now performed routinely in the La Timone Hospital. This partnership was supported by the Association Française contre les Myopathies (AFM).



Institut Pasteur, Paris, France

Genomic Vision has signed a global R&D agreement with the Pasteur Institute: our company has a strong partnership with the Quantitative Image Analysis (AIQ) Unit (Professor Olivo Marin) and the Dynamic Imaging Platform Unit (Professor Spencer Shorte). 




Integrated Technologies Ltd, Ashford, Kent, UK

Genomic Vision and Integrated Technologies Ltd (ITL) have entered into a development agreement in 2011. Established in the UK, ITL is a successful instrumentation design consultancy and manufacturer, with a 35-year experience in developing and manufacturing medical, in vitro diagnostic and analytical instruments. Already firmly embedded in the UK and China, ITL has recently registered its American company and is breaking into the U.S. market.

ITL is supporting Genomic Vision in designing and developing an innovative high-throughput scanning instrument optimized for Molecular Combing assays.